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Relatives of cancer patients are at an increased risk of the same (concordant) cancer but whether they are at a risk for
different (discordant) cancers is largely unknown – beyond well characterized hereditary cancer syndromes - but would be of
major scientific and clinical interest. We therefore decided to resolve the issue by analyzing familial risks when family
members were diagnosed with any discordant cancers. We compared the population impact of concordant to discordant
familial cancer. The Swedish Family-Cancer Database (FCD) was used to calculate familial relative risks (RRs) for family
members of cancer patients, for the 27 most common cancers. Population attributable fractions (PAFs) were estimated for
concordant and discordant family histories. Discordant cancers in the family were detected as significant risk factors for the
majority of cancers, although the corresponding RRs were modest compared to RRs for concordant cancers. Risks increased
with the number of affected family members with the highest RRs for pancreatic (2.31), lung (1.69), kidney (1.98), nervous
system (1.79) and thyroid cancers (3.28), when 5 or more family members were diagnosed with discordant cancers. For most
cancers, the PAF for discordant family history exceeded that for concordant family history. Our findings suggest that there is
an unspecific genetic predisposition to cancer with clinical consequences. We consider it unlikely that shared environmental
risk factors could essentially contribute to the risks for diverse discordant cancers, which are likely driven by genetic
predisposition. The identification of genes that moderately increase the risk for many cancers will be a challenge.
Introduction
Familial risks are reasonably well-known for cancer at the same
(concordant) sites between family members, but the risks
between different (discordant) sites are relatively unknown.1–4
Based on our current understanding the risks at the same sites
could be explained by inherited genetic factors or shared
environmental risk factors.5 For risks between different sites it
is known that germline mutations in genes such as TP53
(Li-Fraumeni syndrome), BRCA1/2 (breast-ovarian cancer syn-
drome) or DNA mismatch repair genes (Lynch syndrome) are
predisposed to a set of cancers, but beyond cancer syndromes
there is no evidence on overall susceptibility to cancer.6 Howev-
er, it is relevant to clinical genetic counseling whether to focus
on a family history of a single or a few cancers, or whether to
record histories of a multitude of cancers. In particular, as can-
cer is present in most families when sufﬁcient information is
available, it would be prudent to understand which tumor types
could be linked on a genetic level and which are likely to be due
to pure chance. For example, if there are cases of melanoma,
colon cancer and leukemia in a family, is there an increased
risk of cancer or is this just a coincidence? For cancer genetics,
mechanism of overall predisposition to many cancers would be
a fascinating, epochal discovery with implications for cancer
prevention and treatment.
Familial risk describes the relative risk of cancer in indi-
viduals whose relatives have been diagnosed with a certain
cancer, compared to those whose relatives that do not have
that cancer. Familial risks are most reliably measured in pop-
ulation based studies where family relationships are known
and cancer diagnoses are medically veriﬁed, typically in data-
bases from, for example, Utah, Iceland or Sweden.1–3 The
familial proportion shows the proportion of individuals in a
given generation or age group with a family member diag-
nosed with a deﬁned cancer.7 This is an interesting measure,
which is only indirectly related to familial risks. The familial
proportion is often cited as ‘familial cancer constitutes X% of
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cancer Y’ but the ﬁgure is often not referenced. Familial pro-
portions are available from population based studies but almost
invariably these are lower, often much lower, than the unrefer-
enced ﬁgures cited by the authors. The population attributable
fraction (PAF) is an estimate of the population impact of a risk
factor: how much would cancer risk decrease if the risk factor
was not present in the population. In the present context, the
PAF depends on the familial risk and the familial proportion,
analogous to environmental epidemiology deﬁning PAF
through the magnitude of the effect and the size of the exposed
population.8 In a previous study we showed that the overall
familial risk of cancer (6%) would rank third after tobacco
smoking (19.4%) and unhealthy diet (9.2%).9,10
In the present study we provide novel estimates for dis-
cordant cancers, including familial risks, familial proportion
and PAF. For comparison we updated our previous estimates
for the same measures in concordant cancers, based on the
recent update of the Swedish Family-Cancer Database, the
largest family dataset in the world.2,10
Materials and Methods
Measures calculated within this study included relative risks,
proportions and PAFs for familial cancer. Familial relative risks
(RRs) for siblings and offspring of cancer patients were assessed
by estimating incidence rate ratios using a Poisson regression
model.11 By this means, incidence rates for people with affected
parents or siblings (positive family history) were compared to
the corresponding rates for those individuals who had no can-
cer (negative family history) among their ﬁrst-degree relatives
(FDRs). Incidence rates were obtained by counting cases and
person-years according to family history and stratiﬁed for sex,
age group, calendar period, residential area and socioeconomic
status to account for potential confounders. These variables
were used as covariates for the model building to get adjusted
RRs and corresponding conﬁdence intervals (CIs) as described
elsewhere.2 Familial risk was considered to be signiﬁcantly
increased if the lower bound of the RR’s 95% CI was >1.00. A
linear trend test was performed. The PAF for familial cancer
deﬁnes the proportion of cancer burden in the population that
is due to an excess familial risk and was calculated as follows8:
PAF5proportion of patients with a positive family history3
RR21
RR
:
We distinguished between family histories, for concordant
and discordant cancers that were deﬁned independently, in
order to assure additive PAFs and to derive overall PAFs for
familial cancer among FDRs.
The abovementioned measures were calculated for the 27
most common cancers based on the Swedish Family Cancer
Database (FCD). The database comprises information from
the Multigeneration Register, censuses and death notiﬁcations
provided by Statistics Sweden, and information from the
Swedish Cancer Registry. The latest version of the FCD
includes data until 2012 and contains 15,713,897 individuals,
whereby all people born in Sweden from 1932 onwards (the
offspring generation) were registered with linkage to their
biological parents (the parental generation). Complete paren-
tal information enabled the identiﬁcation of full siblings and
therefore only individuals with information of both parents
were considered to be at risk, totaling in 8,509,071 index
individuals. The family sizes among the associated nuclear
families varied from a minimum of 3 to a maximum of 20
family members, while the median family comprised of 4
individuals (2 parents and 2 offspring). Among them,
427,196 medically veriﬁed cancer cases were recorded and
only the ﬁrst primary cancers were considered. The 7th revi-
sion of the International Classiﬁcation of Diseases (ICD-7)
was used to identify the cancer type.
The follow-up for cancer was based on the Swedish Can-
cer Registry, starting from the beginning of 1958, the birth
year, or the immigration year, whichever came latest. The
follow-up was terminated when a person was diagnosed with
cancer, emigrated or died, or at the end of 2012, whichever
came ﬁrst. The register-based deﬁnition of period at risk was
used for person-year calculations whereby a person was con-
sidered to be at familial risk irrespective of when family
members were diagnosed with cancer.12
Results
The proportion of cancer patients, who had a concordant
cancer in the family along with the corresponding RRs and
PAFs, are presented in Table 1. All cancers featured signiﬁ-
cantly increased familial risks, although the RRs for connec-
tive tissue cancer and cancer of unknown primary (CUP)
reached a borderline signiﬁcance only. Risks were increased
twofold for most cancers while those of the small intestine
(7.27), thyroid gland (6.70), testis (5.68) and Hodgkin lym-
phoma (5.86) showed the highest RRs. The highest PAFs
were obtained for cancers of the prostate (14.71%), breast
(7.67%) and colorectum (7.11) which cancers also had the
What’s new?
Familial cancer risk is well-established, particularly for cancers of the same (concordant) type. By contrast, little is known
about possible risks when family members are diagnosed with multiple different (discordant) cancers. Here, using data from
the Swedish Family-Cancer Database, familial risks and population impact of concordant and discordant familial cancers were
analyzed for the 27 most common malignancies. The occurrence of discordant cancers in families was found to significantly
increase cancer risk, though not to the same extent as for concordant cancers. The data suggest that a general genetic sus-
ceptibility to cancer exists in some families.
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largest proportions of cases with a concordant cancer in the
family (24.56%, 16.13% and 14.71%, respectively).
Although RRs were only 1.2, or less, regarding a positive
family history for discordant cancers in Table 2, all but
esophageal and endometrial cancers showed signiﬁcantly
increased familial risks. All estimates were based on >1000
familial patients. For 20 out of 27 investigated cancers, more
than half of the patients had at least one discordant cancer in
the family. The proportions ranged from 42.02% for prostate
cancer to 60.85% for small intestinal cancer. High propor-
tions of familial cancer implied high PAFs with a maximum
PAF of 11.78% for small intestinal cancer, followed by 8.54%
for CUP and 8.12% for pancreatic cancer.
Summing up concordant and discordant familial cancers to
estimate the impact of all familial cancer, the proportions ranged
from 46.97% for Hodgkin lymphoma to 66.58% for prostate can-
cer. A PAF of >10% was then observed for 9 cancers, including
stomach (11.33%), small intestinal (13.63%), colorectal (12.16%),
pancreatic (10.54%), lung (13.73%), breast (12.18%), ovarian
(10.50%), prostate (17.81%) and thyroid (10.53%) cancers.
Considering the number of patients with discordant can-
cers in the family revealed an increasing trend for RRs (Table
3). For families with 1 or 2 discordant cancers, most signiﬁ-
cant RRs ranged between 1.02–1.30. For 3 discordant cancers
in the family, RRs for stomach, liver, lung, ovarian, kidney
and thyroid cancers as well as CUP were 1.40 or higher.
CUP even showed an RR of 1.76 for 4 discordant familial
cancers, while the RR increased for stomach (1.70) and endo-
crine glands (1.69) cancers. The highest RRs were obtained
in families presenting with 5 or more discordant cancers. Sig-
niﬁcantly increased RRs were shown for 7 cancers, including
pancreatic (2.31), and kidney (1.98), and nervous system
(1.79) cancer and myeloma (2.20), for which the RRs were
about equal to concordant familial risks from Table 1. Note
that trend tests were highly signiﬁcant for all cancers except
for esophageal cancer.
Table 1. Familial cancer risk and population attributable fraction for concordant cancers.
Cases negative
family history
Any concordant cancer in the family
Cancer site Cases Proportion in % RR 95% CI PAF in %
Upper aerodigestive tract 3508 246 2.83 1.75 (1.47-2.08) 1.22
Esophagus 1110 45 1.63 2.62 (1.77-3.87) 1.01
Stomach 2057 341 6.29 2.17 (1.87-2.53) 3.40
Small intestine 674 39 2.14 7.27 (5.11-10.34) 1.85
Colorectum 13324 5203 14.71 1.94 (1.86-2.01) 7.11
Liver 2383 208 3.53 1.81 (1.51-2.18) 1.58
Pancreas 2494 291 4.42 2.21 (1.89-2.59) 2.42
Lung 8855 2775 11.38 2.36 (2.22-2.51) 6.56
Breast 28471 12310 16.13 1.91 (1.85-1.97) 7.67
Cervix 4103 194 2.17 1.70 (1.43-2.02) 0.89
Endometrium 4431 534 4.74 2.26 (1.98-2.58) 2.64
Ovary 3925 448 4.49 2.95 (2.65-3.28) 2.97
Prostate 20675 15196 24.56 2.49 (2.42-2.57) 14.71
Testis 3984 132 1.76 5.68 (4.48-7.19) 1.45
Kidney 3890 364 3.86 1.97 (1.72-2.26) 1.90
Urinary bladder 5284 886 6.36 1.93 (1.77-2.12) 3.07
Melanoma 11890 1786 6.27 2.72 (2.56-2.90) 3.97
Skin, squamous cell 4578 742 6.40 2.09 (1.90-2.30) 3.34
Nervous system 10947 717 3.22 1.71 (1.54-1.89) 1.33
Thyroid gland 2452 190 3.40 6.70 (5.61-8.01) 2.90
Endocrine glands 4171 282 2.92 2.50 (2.11-2.95) 1.75
Connective tissue 1797 26 0.69 1.79 (0.98-3.28) 0.30
Non-Hodgkin lymphoma 6259 524 3.65 1.78 (1.60-1.97) 1.60
Hodgkin lymphoma 2353 75 1.69 5.86 (4.53-7.59) 1.40
Myeloma 1606 100 2.45 2.23 (1.79-2.78) 1.35
Leukemia 7425 478 3.27 2.02 (1.82-2.25) 1.65
CUP 3600 268 2.92 1.25 (1.00-1.58) 0.59
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Discussion
The present nationwide study covered all 2-generation fami-
lies in Sweden, with a median number of 4 individuals per
family with a maximum of 20 family members. These data
demonstrate 5 novel features of familial cancer. First, of the
27 cancers considered all but esophageal and endometrial
cancers (probably because these are relatively late onset can-
cers) showed a signiﬁcant familial risk for a discordant family
history. Second, the proportion of families with discordant
cancers ranged from 42.02% for prostate cancer to 60.85%
for small intestinal cancer. Combining concordant and dis-
cordant family histories, 66.58% of families with a prostate
cancer had a family history of any cancer, which was the
highest percentage. By contrast, Hodgkin lymphoma showed
the lowest percentage of 46.97%. Third, the above propor-
tions indicate that from 33% to 55% of all families have none
or a single member diagnosed with cancer. The rest have at
least 2 cancer patients. Fourth, even though RRs for any dis-
cordant cancer were considerably smaller than those of con-
cordant cases, because of their higher proportions, discordant
cancers resulted in PAFs which exceeded those for concor-
dant cancer for all but prostate, breast and colorectal cancers.
Fifth, familial risk increased uniformly by the number of
family members with discordant cancer. For pancreatic, kid-
ney and nervous system cancers, myeloma and CUP the RRs
were equal or higher than RRs for concordant cancer when 4
or more family members were diagnosed with discordant
cancer. None of the clusters of discordant cancers could be
explained by known cancer syndromes, and for myeloma and
CUP no such syndromes have even been described.
The results are surprising considering the lack of evidence
on general susceptibility to cancer. This view is embedded in
Table 2. Familial cancer risk and population attributable fraction for discordant cancers.
Cancer site
Cases negative
family history
Any discordant (but no concordant)
cancer in the family All familial cancer
Cases
Proportion
in % RR 95% CI PAF in % Cases
Proportion
in % PAF in %
Upper aerodigestive
tract
3508 4943 56.84 1.10 (1.04-1.17) 5.20 5189 59.66 6.41
Esophagus 1110 1598 58.05 1.05 (0.95-1.16) 2.84 1643 59.68 3.85
Stomach 2057 3021 55.75 1.17 (1.08-1.26) 7.93 3362 62.04 11.33
Small intestine 674 1108 60.85 1.24 (1.12-1.38) 11.78 1147 62.99 13.63
Colorectum 13324 16833 47.60 1.12 (1.09-1.15) 5.05 22036 62.32 12.16
Liver 2383 3302 56.03 1.12 (1.05-1.20) 6.10 3510 59.56 7.69
Pancreas 2494 3806 57.75 1.16 (1.09-1.24) 8.12 4097 62.16 10.54
Lung 8855 12747 52.29 1.16 (1.12-1.20) 7.17 15522 63.67 13.73
Breast 28471 35551 46.57 1.11 (1.08-1.13) 4.52 47861 62.70 12.18
Cervix 4103 4653 51.99 1.06 (1.01-1.12) 3.00 4847 54.16 3.89
Endometrium 4431 6289 55.88 1.05 (0.99-1.11) 2.56 6823 60.63 5.20
Ovary 3925 5597 56.14 1.16 (1.10-1.21) 7.53 6045 60.63 10.50
Prostate 20675 25993 42.02 1.08 (1.05-1.11) 3.10 41189 66.58 17.81
Testis 3984 3397 45.21 1.08 (1.01-1.15) 3.38 3529 46.97 4.83
Kidney 3890 5186 54.94 1.16 (1.10-1.23) 7.78 5550 58.79 9.68
Urinary bladder 5284 7755 55.69 1.14 (1.09-1.19) 6.88 8641 62.05 9.95
Melanoma 11890 14820 52.01 1.10 (1.07-1.14) 4.84 16606 58.27 8.81
Skin, squamous cell 4578 6265 54.08 1.08 (1.03-1.13) 3.90 7007 60.48 7.24
Nervous system 10947 10606 47.62 1.10 (1.05-1.14) 4.17 11323 50.84 5.51
Thyroid gland 2452 2940 52.67 1.17 (1.09-1.25) 7.63 3130 56.07 10.53
Endocrine glands 4171 5216 53.95 1.10 (1.04-1.16) 4.73 5498 56.86 6.48
Connective tissue 1797 1947 51.64 1.17 (1.05-1.30) 7.43 1973 52.33 7.73
Non-Hodgkin lymphoma 6259 7558 52.70 1.09 (1.05-1.13) 4.30 8082 56.36 5.90
Hodgkin lymphoma 2353 2009 45.28 1.10 (1.02-1.18) 4.09 2084 46.97 5.50
Myeloma 1606 2381 58.26 1.09 (1.02-1.17) 4.95 2481 60.70 6.30
Leukemia 7425 6731 46.00 1.11 (1.06-1.15) 4.47 7209 49.26 6.12
CUP 3600 5303 57.82 1.17 (1.08-1.27) 8.54 5571 60.75 9.13
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pathological diversity of cancer as a disease of many organ
systems (sites) and histological types. In accordance, previous
family studies have provided no support to the hypothesis of
an overall susceptibility to cancer. Importantly, their limita-
tion has been pairwise analysis of cancers rather than allow-
ing any combination of cancers in family members.1,3,4,13 The
present data in Table 3 testify to this point; when only one
family member was diagnosed with a discordant cancer most
RRs were below 1.10.
Twin and other type of family data have described a heri-
table component for all cancer but this has been smaller than
that for common individual cancers, and twin studies typical-
ly consider cancer in two individuals.14–16 A recent joint
analysis of genome-wide association studies on 13 different
sporadic cancers provided evidence against genetic sharing
between pairs of cancers.17
Thus the most likely explanation as to why our study
might have been more sensitive than previous negative stud-
ies was that we considered family history of any and many
discordant cancers. Another important factor was the unsur-
passed statistical power of the present study, covering 44,000
concordant and 207,555 discordant familial cancers. The pro-
portions and kinds of familial cancers depend on the age
structure of the generations under study. In the present study
the second generation was born after 1931; thus the oldest
individuals reached age 80 in the last follow-up year of 2012.
This is well past the median age of cancer diagnosis in the
Swedish Cancer Registry, which is 70 years.18 However, as
the median birth year of the second generation was 1947,
this age cohort only reached their 65th birthday year in 2012.
Thus cancers in the second generation have a modest over-
representation of early onset cancers. Early age of onset fea-
tures many but not all familial cancers19; however we did not
carry out age-speciﬁc analysis because considering ages of
onset of all family members with different cancers would be
utterly complex. In a recent study on discordant cancers in
prostate cancer families, the differences by age of onset were
modest.20 Another variable with possible inﬂuence on the
results is the family size. We assume however that familial
risks would not be inﬂuenced because a 3-generation analysis
from this Database showed that the proportions of cancers
were relatively uniform and without systematic trends, even
when the family sizes varied from <5 to >60 individuals.21
The present results were internally credible because a clear
‘dose-response’ relationship was observed in risk increase by
the number of affected relatives with discordant cancer.
It is unlikely that shared environmental risk factors could
essentially contribute to the risks for diverse discordant can-
cers. Even the risk factors that are known to inﬂuence can-
cers at several sites and which have a genetic component,
including tobacco smoking and obesity, would not have a
major inﬂuence on cancers, such as prostate and breast can-
cers.22 In the same vein, environmental risk factors shared by
family members are difﬁcult to demonstrate even in the
spousal setting, with the exception of smoking related
cancers.10,23 Thus the most likely explanation to the observed
clustering of discordant cancers in families is genetic predis-
position, possibly with interacting environmental factors.
Second and multiple primary cancers account for over
20% of the notiﬁcations to the Swedish Cancer Registry.18
There is a large body of literature on second primary cancers
which generally shows that the patients are at an increased
risk of any cancer, including discordant cancer.24–26 The risks
are known to interact with the family history for discordant
cancer, which would be in line with the current ﬁndings.27,28
Although multiple primary cancers can have many etiologies
the presentation of discordant cancers may in part be an
expression of an overall cancer risk at the individual level,
which may be enforced by a family history of cancer.
The best examples of predisposing genes with pleotropic
effects on multiple cancer are found in the domain of cancer
syndromes caused by tumor suppressor genes, all of which
were initially linked to one or a few cancers but in the course of
time more involved sites of lower risk were identiﬁed.6 For
example, hereditary nonpolyposis colorectal cancer (HNPCC,
Lynch syndrome), caused by mutations in mismatch repair
genes, was initially identiﬁed in colorectal cancer families, but it
was later associated with a high risk of endometrial cancer and
with a somewhat lower risk of many other cancers.29 BRCA1
and BRCA2, also caused by mutations in DNA repair, were
identiﬁed in breast and ovarian cancer families but now several
other cancers are linked to these mutations.30
Pathways including tumor suppressor genes are involved
in essential cellular processes shared by many tissues, which
is the biological rationale why damage in such genes would
have pleiotropic effects. Such critical cancer promoting cellu-
lar processes have been coined as ‘hallmarks of cancer’.31–34
It is conceivable that many key genes in such pathways could
be polymorphic or under control of distal regulators which
would inﬂuence the general risk of cancer, resulting in an
unspeciﬁc increase in cancer risk perhaps through impaired
immune surveillance or chronic inﬂammation. Examples of
such pleiotropic polymorphisms are emerging in various can-
cers.35–37 Most tumor suppressor genes support a single or a
few cellular processes but recently detected ‘super enhancers’
are key regulatory elements of gene pathways, potentially
promoting oncogenic processes in many cancers.38,39 While
the importance of super enhancers remains to be established
we could speculate that they cause, at most, modest pleo-
tropic risks because high-risk genes would have been identi-
ﬁed in high-risk cancer families.
In conclusion, the present data have major clinical and
mechanistic implications. Although the existence of several
cancer predisposition syndromes is now well established and
appreciated also by practicing oncologists, our ﬁndings shed
light on an enigmatic but very common group of patients.
Such patients have families with a collection of different
tumors without seeming to ﬁt any of the well-known syn-
dromes. Our ﬁndings indicate that there is indeed a more
unspeciﬁc type of genetic predisposition to cancer. This has
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immediate clinical consequences. In the general practice, a
patient with a strong history of “various tumors” should be
taken seriously if there are signs and symptoms suggestive of
cancer. In the oncology practice, these patients should be
monitored not only for the relapse of the presenting tumor
but tumors elsewhere. This is easily achieved with modern
imaging techniques such as computer tomography and posi-
tron emission tomography. For genetic counseling, it will be
useful to realize that there is such a thing as unspeciﬁc cancer
predisposition which may increase the susceptibility for many
tumor types. However, our ﬁndings would have further prac-
tical relevance if the molecular reasons for the observed can-
cer risk could be deﬁned. In medicine, it remains as true as
ever that establishing causality on a molecular level remains
key for designing interventions.
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